191 related articles for article (PubMed ID: 22306125)
21. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).
Lilenbaum RC; Herndon JE; List MA; Desch C; Watson DM; Miller AA; Graziano SL; Perry MC; Saville W; Chahinian P; Weeks JC; Holland JC; Green MR
J Clin Oncol; 2005 Jan; 23(1):190-6. PubMed ID: 15625373
[TBL] [Abstract][Full Text] [Related]
22. [The correlation between chemotherapeutic efficacy and breast cancer susceptibility gene 1 and class IIIβ-tubulin protein expression in non-small cell lung cancer patients].
Wan YY; Hui HX; Wang XW; Sun SA; Wu J
Zhonghua Nei Ke Za Zhi; 2011 Jun; 50(6):469-73. PubMed ID: 21781528
[TBL] [Abstract][Full Text] [Related]
23. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel.
Sève P; Mackey J; Isaac S; Trédan O; Souquet PJ; Pérol M; Lai R; Voloch A; Dumontet C
Mol Cancer Ther; 2005 Dec; 4(12):2001-7. PubMed ID: 16373715
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
[TBL] [Abstract][Full Text] [Related]
25. A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.
Zimling ZG; Sørensen JB; Gerds TA; Bech C; Andersen CB; Santoni-Rugiu E
Cancer Chemother Pharmacol; 2012 Nov; 70(5):743-54. PubMed ID: 22960937
[TBL] [Abstract][Full Text] [Related]
26. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.
Monzó M; Rosell R; Sánchez JJ; Lee JS; O'Brate A; González-Larriba JL; Alberola V; Lorenzo JC; Núñez L; Ro JY; Martín C
J Clin Oncol; 1999 Jun; 17(6):1786-93. PubMed ID: 10561216
[TBL] [Abstract][Full Text] [Related]
27. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.
Tommasi S; Mangia A; Lacalamita R; Bellizzi A; Fedele V; Chiriatti A; Thomssen C; Kendzierski N; Latorre A; Lorusso V; Schittulli F; Zito F; Kavallaris M; Paradiso A
Int J Cancer; 2007 May; 120(10):2078-85. PubMed ID: 17285590
[TBL] [Abstract][Full Text] [Related]
28. Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients.
Jakobsen JN; Santoni-Rugiu E; Sørensen JB
Cancer Chemother Pharmacol; 2014 Jan; 73(1):43-51. PubMed ID: 24220933
[TBL] [Abstract][Full Text] [Related]
29. Class III Beta-tubulin Expression in Non-small Cell Lung Cancer: A Predictive Factor for Paclitaxel Response.
Ohashi T; Yoshimasu T; Oura S; Kokawa Y; Kawago M; Hirai Y; Miyasaka M; Aoishi Y; Kiyoi M; Nishiguchi H; Honda M; Okamura Y
Anticancer Res; 2015 May; 35(5):2669-74. PubMed ID: 25964544
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer.
Urano N; Fujiwara Y; Doki Y; Kim SJ; Miyoshi Y; Noguchi S; Miyata H; Takiguchi S; Yasuda T; Yano M; Monden M
Int J Oncol; 2006 Feb; 28(2):375-81. PubMed ID: 16391792
[TBL] [Abstract][Full Text] [Related]
31. Recent advances with chemotherapy for NSCLC: the ECOG experience. Eastern Cooperative Oncology Group.
Johnson DH; Chang AY; Ettinger DS; Kim KM; Bonomi P
Oncology (Williston Park); 1998 Jan; 12(1 Suppl 2):67-70. PubMed ID: 9516615
[TBL] [Abstract][Full Text] [Related]
32. Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer.
Rosell R; Felip E
Semin Oncol; 2001 Aug; 28(4 Suppl 14):37-44. PubMed ID: 11605182
[TBL] [Abstract][Full Text] [Related]
33. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?
Sève P; Dumontet C
Lancet Oncol; 2008 Feb; 9(2):168-75. PubMed ID: 18237851
[TBL] [Abstract][Full Text] [Related]
34. Combination of microtubule associated protein-tau and β-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer.
Yu J; Gao J; Lu Z; Gong J; Li Y; Dong B; Li Z; Zhang X; Shen L
Eur J Cancer; 2014 Sep; 50(13):2328-35. PubMed ID: 25016949
[TBL] [Abstract][Full Text] [Related]
35. High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway.
Levallet G; Bergot E; Antoine M; Creveuil C; Santos AO; Beau-Faller M; de Fraipont F; Brambilla E; Levallet J; Morin F; Westeel V; Wislez M; Quoix E; Debieuvre D; Dubois F; Rouquette I; Pujol JL; Moro-Sibilot D; Camonis J; Zalcman G;
Mol Cancer Ther; 2012 May; 11(5):1203-13. PubMed ID: 22411898
[TBL] [Abstract][Full Text] [Related]
36. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis.
Delbaldo C; Michiels S; Syz N; Soria JC; Le Chevalier T; Pignon JP
JAMA; 2004 Jul; 292(4):470-84. PubMed ID: 15280345
[TBL] [Abstract][Full Text] [Related]
37. Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.
Miyata Y; Matsuo T; Nakamura Y; Yasuda T; Ohba K; Takehara K; Sakai H
Anticancer Res; 2018 Mar; 38(3):1629-1635. PubMed ID: 29491095
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer.
Sun R; Liu Z; Wang L; Lv W; Liu J; Ding C; Yuan Y; Lei G; Xu C
Tumour Biol; 2015 Sep; 36(9):7195-204. PubMed ID: 25894372
[TBL] [Abstract][Full Text] [Related]
39. Regulation of β-tubulin isotypes by micro-RNA 100 in MCF7 breast cancer cells.
Lobert S; Jefferson B; Morris K
Cytoskeleton (Hoboken); 2011 Jun; 68(6):355-62. PubMed ID: 21634028
[TBL] [Abstract][Full Text] [Related]
40. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.
Reiman T; Lai R; Veillard AS; Paris E; Soria JC; Rosell R; Taron M; Graziano S; Kratzke R; Seymour L; Shepherd FA; Pignon JP; Sève P
Ann Oncol; 2012 Jan; 23(1):86-93. PubMed ID: 21471564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]